Epigral Limited has recommended a final dividend of ₹5 per equity share for the financial year ended March 2026, as announced by its Board of Directors on May 2, 2026. The company also submitted its financial results for the quarter ended June 30, 2026, to the NSE on July 27, 2026, providing investors with a fuller picture of its near-term earnings trajectory alongside the payout history.

Dividend Details

The ₹5 final dividend for FY26 represents a 43% increase over the standalone final dividend of ₹3.5 declared for FY25. However, when compared against the total FY25 payout of ₹6 per share (which included a ₹2.5 interim tranche), the FY26 standalone final payout of ₹5 reflects a lower aggregate distribution for the year, provided no interim dividend was declared in FY26. Investors should note that no interim dividend announcement has been recorded for FY26 in the available NSE filings.

Dividend History and Trend

Epigral Limited, which operated as Meghmani Finechem Limited until its rebranding, has maintained a consistent dividend distribution track record since at least FY23. The consolidated dividend history is as follows:

The trend indicates the company has sustained per-share payouts broadly in the ₹5 to ₹6 range over the past three fiscal years, signalling a stable, if not aggressively growing, dividend policy. The FY26 final dividend matches the FY24 final dividend exactly at ₹5 per share.

Market Context

As the quote and trade information were not available at the time of this report, a precise dividend yield calculation and 52-week range context cannot be provided. Investors are advised to check the live NSE price of EPIGRAL (ISIN: INE071N01016) to compute the dividend yield by dividing ₹5 by the prevailing market price. For reference, at a hypothetical price of ₹500, the yield would be 1.0%; at ₹1,000, the yield would be 0.5%. The stock's current price relative to its 52-week range would further determine how the dividend compares to prevailing market valuations in the specialty chemicals segment.

Company Background

Epigral Limited, formerly Meghmani Finechem Limited, is a specialty chemicals manufacturer with operations in chlor-alkali and downstream derivatives. The company rebranded to Epigral to reflect its expanded product portfolio and strategic positioning in the fluorochemicals and performance chemicals space. It is listed on the NSE and falls under the broader specialty chemicals sector, which has experienced both margin pressures and volume recovery over recent quarters.

What It Means for Investors

The consistent maintenance of the ₹5 per share final dividend level across FY24 and FY26 suggests the Board is committed to returning capital to shareholders even as the company navigates sector-level headwinds. However, the apparent absence of an interim dividend in FY26 compared to FY25 means the total annual payout may be lower year-on-year. Investors tracking dividend income from this counter should await confirmation of whether any additional interim payout was declared outside the current NSE filing window before drawing conclusions on the full-year distribution for FY26.